Didnt get chance to answer a great Q on @sarahjulianotts show on @BBCNottingham about having #COVID19#vaccine the starting #immunotherapy. If the therapy is designed to dampen down your immunity, then it might reduce the overall level of immunity that the vaccine produces.
But in this case, the therapy will start 14 days after vaccine, by which time immunity has often peaked (with Pfizer, maybe slight increase with AZ after this time). Therefore, the therapy will have very little, if any, impact.
And if you are currently on immunotherapy, then the vaccine committee have not precluded you from having the vaccine. Even if the overall response is reduced, I think in most people it will still offer some protection. Worried or unsure - ask your clinical orvaccination team👍
And @sarahjulianotts, this weekend I will walk the dog, AND go horse-riding, as that now is allowed. Saddle up 🐎
Not ‘some’ protection, ‘good’ protection is what I meant!
• • •
Missing some Tweet in this thread? You can try to
force a refresh
@Psynian 1/n
Not sure I align to his views.
The virus is mutating, there is evidence/suggestion that some of those might change virus behaviour. There’s a spike change (amino acid 614) that increases infectivity of virus when grown in the lab.
@Psynian 2/n
But we don’t know if this increases infectivity, disease severity or transmissibility in humans.
@Psynian 3/n
There’s also a deletion that removes one of the non-structural genes (ORF8), which is thought to down regulate antigen presentation. nature.com/articles/s4157…
Thanks to @JanetDaly5 for flagging this. First animal data from #chadox1#SARSCoV2 vaccine. Not sterilising immunity, but reduced viral load and pathogenesis, with half dose, BUT very quick challenge 4 week. (recall questioning this previously): biorxiv.org/content/10.110…
1/n worth considering these data in detail; and what they might or might not mean
2/n Firstly, the challenge dose. This was a relatively large amount of virus, BUT for people exposed to virus for considerable periods of time and/or large amounts (household member or healthcare worker) then protection against higher viral load exposure is relevant.
1/n Really pleased to hear that #nCoV2019 testing will be ramped up in the UK - it wont be easy but it will be worth it.
Heard some concerns about how well a nose/throat swab will work.
2/n But I think that those concerns can be allayed by thinking about where most of the viral replcaition is taking place in different presentations/stages of the disease.
3/n In a hospital setting (where initial concerns were raised about the sensitivity of the testing and sampling), the admissions will have pneumonia so most replication will likely be happening deep in the lungs - a throat swab might not be great
1/n One if the reasons we should all do our bit is tgat here in the UK, according to this study: ncbi.nlm.nih.gov/pubmed/30857602
There is 1 critical care (ICU/IDU) bed per 10,000 people.
2/n There are approximately 65M people living in the UK. None of whom will have immunity to #nCoV2019 (except the tiny fraction that have already been infected).
3/n The estimates for the number of people that could be infected in the first wave of the epidemic is impossible to predict, but let’s take a conservative estimate of 30%. Thats 65M x 0.3 = 19.5M. If it was lower, say 10% then that would be 6.5M